Clinics and Practice, Volume 12, Issue 1
2022 February - 18 articles
Cover Story: In ophthalmology, there is a clinical condition called macular hole, and its origin is diverse (myopic, idiopathic, traumatic, among others); the only treatment available today is surgery. The goal is to achieve closure of the macular hole and recover visual function as much as possible; however, success is not achieved in some cases with the standard surgical technique. Plasma Rich in Growth Factors (PRGF-Endoret®) of autologous origin has demonstrated its role in corneal regeneration in clinical and basic research. The use of the membrane formulation of PRGF (mPRGF) in this clinical research article, used as an adjuvant therapy to the standard surgical technique, has demonstrated its efficacy in closing the macular hole and at the same time restoring the retinal layers. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
